致癌与突变杂志

抽象的

PPARγ-independent Activity of Thiazolidinediones: A Promising Mechanism of Action for New Anticancer Drugs?

Isabelle Grillier-Vuissoz, Sabine Mazerbourg, Michel Boisbrun, Sandra Kuntz, Yves Chapleur and Stéphane Flament

Thiazolidinediones are agonists of the nuclear receptor Peroxisome Proliferator Activated Receptor gamma (PPARγ). These synthetic compounds are known for a long time to have anticancer potencies and numerous studies have been performed to understand their mechanism of action. An increasing amount of converging results indicate that most of these mechanisms appear in a PPARγ-independent manner. This was suggested by the observation of effects in cell types devoid of PPARγ and by the absence of correlation between agonist efficiencies and the intensity of the effects. The PPARγ-independence was demonstrated by various experimental approaches using PPARγ antagonists, RNA interference targeting PPARγ or thiazolidinedione derivatives devoid of PPARγ agonist activity. Here, we review the studies that describe PPARγ-independent changes including ionic changes (intracellular pH and Ca2+), reactive oxygen species production, Mitogen Activated Protein Kinases activation, endoplasmic reticulum stress and proteasomal degradation of key proteins. The relationships between these events that occur either early or late after thiazolidinedione exposure and their possible involvement in the antineoplastic effect are discussed. We conclude about the possibility to take advantage from these data to develop new thiazolidinedione derivatives usable as anticancer drugs.